Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Receives $3.02 Average PT from Analysts

Shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOXGet Rating) have earned a consensus rating of “Buy” from the five ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $2.78.

ELOX has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Eloxx Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 5th. B. Riley decreased their target price on shares of Eloxx Pharmaceuticals from $5.00 to $3.00 in a report on Monday, January 24th. Finally, HC Wainwright reduced their price target on shares of Eloxx Pharmaceuticals to $1.00 in a research report on Monday, May 9th.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN raised its position in Eloxx Pharmaceuticals by 118.4% during the fourth quarter. Wells Fargo & Company MN now owns 46,670 shares of the company’s stock valued at $33,000 after acquiring an additional 25,300 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Eloxx Pharmaceuticals in the fourth quarter valued at approximately $91,000. Geode Capital Management LLC raised its position in shares of Eloxx Pharmaceuticals by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 798,058 shares of the company’s stock valued at $558,000 after purchasing an additional 25,222 shares during the period. B. Riley Wealth Management Inc. bought a new position in shares of Eloxx Pharmaceuticals in the fourth quarter valued at approximately $34,000. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Eloxx Pharmaceuticals in the fourth quarter valued at approximately $831,000. 28.25% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ELOX traded down $0.01 during midday trading on Monday, hitting $0.34. The stock had a trading volume of 151,682 shares, compared to its average volume of 284,791. Eloxx Pharmaceuticals has a fifty-two week low of $0.21 and a fifty-two week high of $2.53. The business has a 50-day simple moving average of $0.41 and a two-hundred day simple moving average of $0.58. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.20 and a current ratio of 2.20.

Eloxx Pharmaceuticals (NASDAQ:ELOXGet Rating) last announced its earnings results on Thursday, March 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). On average, equities research analysts expect that Eloxx Pharmaceuticals will post -0.48 earnings per share for the current year.

About Eloxx Pharmaceuticals (Get Rating)

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.

Further Reading

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.